-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Huajin Pharmaceutical, which is committed to the development of innovative biological anti-tumor drugs, announced the completion of tens of millions of US dollars in pre-B round financi.
It is reported that this round of financing will be mainly used for the research and development of original first-in-class oncolytic bacteria products, to promote the development of the world’s first tumor-targeted amino acid metabolism pathway-regulated oncolytic bacterial biological product SGN1, and to accelerate its clinical application worldwi.
pipeline proce.
In fact, financing in the pharmaceutical industry is very comm.
Because it is conducive to further optimizing the layout of the R&D pipeline, it has always been a beautiful landscape in the pharmaceutical fie.
It is understood that since this year, the biopharmaceutical industry has been setting off a wave of financi.
The data shows that in the first quarter, financing in China's biopharmaceutical field (excluding in vitro diagnostics and testing, e.
) was very active as a whole, with more than 90 Chinese biopharmaceutical companies completing financing of different rounds and natur.
It is worth mentioning that more than 50 new drug R&D companies have completed early-stage financing (A round/A+ round and befor.
Among them, in April this year, a total of 78 financing events occurred in the biomedical field nationwide, with a cumulative amount of 909 billion yu.
Compared with the previous month, the financing events decreased by 209%, and the financing amount decreased by 57
In terms of the number of financings, there are more financing events in the A round and the Pre-A round, 19 and 14 respective.
In terms of the amount of financing, the highest financing amount in the A round is 288 billion yuan; secondly, the financing amount in the A+ round is also more prominent, with a financing amount of 020 billion yu.
In terms of financing amount, 78 financing events occurred in April, including 33 financings with a financing amount of more than 100 million yuan, 36 financings with a financing amount of 10 million yuan, and 9 financing events with an undisclosed financing amou.
At present, from the perspective of the industry as a whole, this wave of financing is still continui.
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for new drug research and development, promotion,e.
For example, a few days ago, Suzhou U-Synbio Technology .
, L.
(hereinafter referred to as "U-Synbio") also announced the completion of an angel round of financing of tens of millions, which was jointly invested by Inno Angel, Suzhou Industrial Park Science and Technology Innovation Fund and Shuimu Tsingh.
This round of financing is mainly used for the company's team development, laboratory construction, development of a series of pipeline products, as well as the optimization and upgrading of the core technology platform and external cooperati.
According to the data, U-Synbio is a technology-driven synthetic biology medical application technology compa.
In the next few years, Youqi will use synthetic biology technology to improve the living biological drug technology platform, and focus on the development of a series of pipeline products for rare metabolic diseases, so as to create greater value for human heal.
Prior to this, Zhejiang Maitong Biopharmaceutical .
, L.
(hereinafter referred to as "Maitong Bio") announced the completion of the A round of financi.
This round of financing was exclusively invested by Chairman Cai Xiang of Longtian Pharmaceutical Gro.
It is reported that the funds raised in this round of financing will be used to advance the clinical trials of small molecule inhibitors of the IDH1 pipeline and further accelerate the research and development of other innovative clinical pipelines of the compa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
It is reported that this round of financing will be mainly used for the research and development of original first-in-class oncolytic bacteria products, to promote the development of the world’s first tumor-targeted amino acid metabolism pathway-regulated oncolytic bacterial biological product SGN1, and to accelerate its clinical application worldwi.
pipeline proce.
In fact, financing in the pharmaceutical industry is very comm.
Because it is conducive to further optimizing the layout of the R&D pipeline, it has always been a beautiful landscape in the pharmaceutical fie.
It is understood that since this year, the biopharmaceutical industry has been setting off a wave of financi.
The data shows that in the first quarter, financing in China's biopharmaceutical field (excluding in vitro diagnostics and testing, e.
) was very active as a whole, with more than 90 Chinese biopharmaceutical companies completing financing of different rounds and natur.
It is worth mentioning that more than 50 new drug R&D companies have completed early-stage financing (A round/A+ round and befor.
Among them, in April this year, a total of 78 financing events occurred in the biomedical field nationwide, with a cumulative amount of 909 billion yu.
Compared with the previous month, the financing events decreased by 209%, and the financing amount decreased by 57
In terms of the number of financings, there are more financing events in the A round and the Pre-A round, 19 and 14 respective.
In terms of the amount of financing, the highest financing amount in the A round is 288 billion yuan; secondly, the financing amount in the A+ round is also more prominent, with a financing amount of 020 billion yu.
In terms of financing amount, 78 financing events occurred in April, including 33 financings with a financing amount of more than 100 million yuan, 36 financings with a financing amount of 10 million yuan, and 9 financing events with an undisclosed financing amou.
At present, from the perspective of the industry as a whole, this wave of financing is still continui.
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for new drug research and development, promotion,e.
For example, a few days ago, Suzhou U-Synbio Technology .
, L.
(hereinafter referred to as "U-Synbio") also announced the completion of an angel round of financing of tens of millions, which was jointly invested by Inno Angel, Suzhou Industrial Park Science and Technology Innovation Fund and Shuimu Tsingh.
This round of financing is mainly used for the company's team development, laboratory construction, development of a series of pipeline products, as well as the optimization and upgrading of the core technology platform and external cooperati.
According to the data, U-Synbio is a technology-driven synthetic biology medical application technology compa.
In the next few years, Youqi will use synthetic biology technology to improve the living biological drug technology platform, and focus on the development of a series of pipeline products for rare metabolic diseases, so as to create greater value for human heal.
Prior to this, Zhejiang Maitong Biopharmaceutical .
, L.
(hereinafter referred to as "Maitong Bio") announced the completion of the A round of financi.
This round of financing was exclusively invested by Chairman Cai Xiang of Longtian Pharmaceutical Gro.
It is reported that the funds raised in this round of financing will be used to advance the clinical trials of small molecule inhibitors of the IDH1 pipeline and further accelerate the research and development of other innovative clinical pipelines of the compa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
